Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular Dystrophy [EARLY_Phase 1]

View source ↗

Summary

A pediatric Phase 1 study evaluating safety and tolerability of the investigational drug RAG-18 in Duchenne muscular dystrophy is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• RAG-18

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Duchenne Muscular Dystrophy (DMD) | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING